Search research articles
Contact Us
Filters
Showing results (321-330 of 509) with videos related to
Page
of 51
Sort By:
JAMA Oncology
|
October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial
Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 10, 2026
Gender and regional equity in the European Society of Gynaecological Oncology: a longitudinal analysis of a professional medical society
Tibor A Zwimpfer, Houssein El Hajj, Alina E Sturdza, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 1, 2019
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Denis Querleu, François Planchamp, Luis Chiva, et al.
Annals of Surgical Oncology
|
November 28, 2019
Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study
Mathias Neron, Christophe Sajous, Simon Thezenas, et al.
BMC Medicine
|
April 11, 2017
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
Marion Savina, Axel Le Cesne, Jean-Yves Blay, et al.
Gynecologic Oncology
|
September 16, 2022
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group
Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Journal of the National Cancer Institute
|
December 29, 2020
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial
Céline Callens, Dominique Vaur, Isabelle Soubeyran, et al.
Page
of 51
Search research articles
Search
Showing results (321-330 of 509) with videos related to
Sort By:
Page
of 51
JAMA Oncology
|
October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial
Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 10, 2026
Gender and regional equity in the European Society of Gynaecological Oncology: a longitudinal analysis of a professional medical society
Tibor A Zwimpfer, Houssein El Hajj, Alina E Sturdza, et al.
Bulletin Du Cancer
|
November 26, 2015
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]
Vincent Launay-Vacher, Nicolas Janus, Philippe Beuzeboc, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 1, 2019
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Denis Querleu, François Planchamp, Luis Chiva, et al.
Annals of Surgical Oncology
|
November 28, 2019
Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study
Mathias Neron, Christophe Sajous, Simon Thezenas, et al.
BMC Medicine
|
April 11, 2017
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
Marion Savina, Axel Le Cesne, Jean-Yves Blay, et al.
Gynecologic Oncology
|
September 16, 2022
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group
Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
Journal of the National Cancer Institute
|
December 29, 2020
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial
Céline Callens, Dominique Vaur, Isabelle Soubeyran, et al.
Page
of 51